Toronto Stock Exchange · Healthcare
Invest in Knight Therapeutics stock from India
Indian and foreign residents can buy Knight Therapeutics (GUD) shares directly through Paasa.
By Paasa · Updated
Knight Therapeutics at a glance
- Price
- CA$10.35+CA$0.08 (0.78%)
- Market cap
- CA$1.02B
- Day range
- CA$10.16 – CA$10.41
- P/E
- 70.36
- Dividend yield
- None
- Volume
- 53.65K
- 1 month
- +9.29%
- 6 months
- +43.75%
- YTD
- +71.07%
- 1 year
- +74.83%
- 5 years
- +93.46%
Knight Therapeutics statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CA$450.1M | CA$371.3M | CA$328.2M | CA$293.6M | CA$243.5M |
| Gross profit | CA$150.7M | CA$174.4M | CA$152.7M | CA$138.1M | CA$115.4M |
| Operating income | −CA$2.2M | CA$7.4M | −CA$2.9M | −CA$2.4M | −CA$5.3M |
| Net income | −CA$5.4M | CA$4.3M | −CA$16.8M | −CA$29.9M | CA$15.7M |
| Earnings per share | −CA$0.05 | CA$0.04 | −CA$0.16 | −CA$0.26 | CA$0.13 |
| EBITDA | CA$54.4M | CA$64.4M | CA$40.9M | CA$25.3M | CA$42.6M |
| Total assets | CA$1.0B | CA$963.8M | CA$945.5M | CA$1.1B | CA$991.9M |
| Total debt | CA$77.9M | CA$49.5M | CA$69.1M | CA$77.7M | CA$41.0M |
| Cash and short-term investments | CA$95.3M | CA$172.8M | CA$154.4M | CA$185.6M | CA$163.0M |
| Shareholders' equity | CA$767.3M | CA$795.1M | CA$746.9M | CA$825.9M | CA$842.0M |
| Operating cash flow | CA$70.3M | CA$36.3M | CA$35.9M | CA$40.5M | CA$44.6M |
| Free cash flow | CA$68.4M | CA$4.8M | CA$26.0M | CA$14.7M | −CA$179.6M |
| Capital expenditure | −CA$1.9M | −CA$31.5M | −CA$10.0M | −CA$25.8M | −CA$224.2M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CAD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Bright Minds Biosciences | DRUG.CN | $71.27 | $697.53M |
| Verano | VRNO.NE | CA$8.52 | CA$629.78M |
| Kneat | KSI.TO | CA$6.50 | CA$624.86M |
| Vitalhub | VHI.TO | CA$7.33 | CA$463.69M |
| Cresco Labs | CL.CN | $1.03 | $364.85M |
| Aurora Cannabis | ACB.TO | CA$5.71 | CA$353.69M |
| Cipher Pharmaceuticals | CPH.TO | CA$13.69 | CA$347.61M |
| TerrAscend | TSND.TO | CA$0.88 | CA$272.07M |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- —
- High
- —
- Median
- —
- Consensus
- —
Ratings: 1 buy · 0 hold · 0 sell. Consensus: Buy.
Published sell-side 12-month targets in CAD, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in Knight Therapeutics from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CAD when you buy.
Step 3
Search GUD and buy
Find Knight Therapeutics by name or by its ticker, GUD, and place your order.
Why invest in Knight Therapeutics from India
What Knight Therapeutics does
Knight Therapeutics Inc., a specialty pharmaceutical enterprise established in Montreal, Canada in 2013, operates globally, with a strong presence across Canada and Latin America. The company's core business revolves around the development, acquisition, in-licensing, out-licensing, promotion, and distribution of a diverse portfolio encompassing pharmaceutical products, consumer health goods, and medical devices. Knight Therapeutics operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Knight Therapeutics stock from India?
Yes. Indian residents and NRIs can buy Knight Therapeutics (GUD) shares directly through Paasa. Knight Therapeutics is listed on the Toronto Stock Exchange, in the Drug Manufacturers - Specialty & Generic industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Knight Therapeutics shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CAD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.